unresponsive wakefulness syndrome not otherwise explained
Conditions
Brief summary
A patient will bedefined as a responder if he/she improves by at least 3 points on the GCS after 5 days oftreatment at study visit 6
Detailed description
The secondary objective is Improvement of vigilance measured via alternative scales(Richmond Agitation-Sedation Scale (RASS), Full Outline of UnResponsiveness(FOUR) Score Coma Scale), Intensive Care Delirium Screening Checklist (ICDSC),National Institute of health Stroke Scale (NIHSS), modified Rankin Scale (mRS),Glasgow Outcome Scale – Extended (GOS-E), Coma Recovery Scale revised (CRSR)and Montreal Cognitive Assessment (MoCA) after 90 days, EEG results, survivaland clinical improvement r
Interventions
DRUGAmantadin-ratiopharm® 200 mg Infusionslösung
Sponsors
Universitaetsklinikum Tuebingen AöR
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A patient will bedefined as a responder if he/she improves by at least 3 points on the GCS after 5 days oftreatment at study visit 6 | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objective is Improvement of vigilance measured via alternative scales(Richmond Agitation-Sedation Scale (RASS), Full Outline of UnResponsiveness(FOUR) Score Coma Scale), Intensive Care Delirium Screening Checklist (ICDSC),National Institute of health Stroke Scale (NIHSS), modified Rankin Scale (mRS),Glasgow Outcome Scale – Extended (GOS-E), Coma Recovery Scale revised (CRSR)and Montreal Cognitive Assessment (MoCA) after 90 days, EEG results, survivaland clinical improvement r | — |
Countries
Germany
Outcome results
None listed